Real-world Secukinumab Outcomes in Canadian HS Patients (HS-RISE)

Novartis

Status: Enrolling

Conditions: Hidradenitis Suppurativa

Study type: Observational

Funder types: Industry

Identifiers

NCT07282015

CAIN457MCA01

Details and patient eligibility

About

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

Enrollment: 142 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.
2. Adult patients at the time of informed consent signature.
3. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.
4. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.
5. Patients who can understand written and spoken Canadian English or French.

Exclusion criteria

1. Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.
2. Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM.
3. Patients who have had any prior exposure to secukinumab (i.e., >7 days prior to the baseline visit).

Trial design

142 participants in 1 patient group

Secukinumab

Description:

Patients with moderate-to-severe HS who are prescribed secukinumab in Canadian routine clinical practice